Keeping the Myriad Patent Decision in Perspective

A federal court's decision to overturn two of Myriad's gene patents is not the end of the story, experts say. There's still a lot to consider.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.